GlassScriptPhysician profile
Lily J Tsai
NPI 1184633638
$3,238.53
in general payments reported to CMS, 2019-2025
33 companies · $612 in 2025
The $612 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $71.32 · 2021: $143 · 2022: $72.15 · 2023: $839 · 2024: $866 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,133 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,132.71 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,082.10 | 2023-2025 | Veozah |
| Abbvie INC. | $499.79 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Sumitomo Pharma America, INC. | $168.29 | 2023-2025 | Myfembree |
| Intuitive Surgical, INC. | $144.36 | 2019 | |
| Mayne Pharma Commercial LLC | $116.33 | 2023-2025 | |
| Shield Therapeutics INC | $114.44 | 2023-2024 | Accrufer |
| Hologic Sales and Service, LLC | $107.14 | 2019-2025 | Aptima, Myosure Tissue Removal Device, Acessa Provu System |
| Meditrina | $100.81 | 2024-2025 | |
| Evofem Biosciences, INC. | $99.08 | 2024-2025 | Solosec, Phexx, Phexxi |
| Pfizer INC. | $89.89 | 2022-2024 | |
| Coopersurgical, INC. | $66.69 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $63.09 | 2019-2025 | |
| Allergan, INC. | $61.71 | 2019-2020 | |
| Lupin INC. | $42.36 | 2019 | |
| Therapeuticsmd, INC. | $42.03 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $39.94 | 2025 | Zurzuvae |
| Roche Diagnostics Corporation | $36.59 | 2019 | |
| Aspira Women'S Health INC | $36.24 | 2023-2024 | Ova1 |
| Millicent US INC | $34.27 | 2025 | Femlyv, Intrarosa |
| Duchesnay USA Incorporated | $32.47 | 2019 | |
| Merck Sharp & Dohme LLC | $30.78 | 2019 | |
| Exeltis, USA INC. | $30.73 | 2019 | |
| Applied Medical Resources Corporation | $28.95 | 2023 | |
| Viiv Healthcare Company | $21.90 | 2025 | Apretude |
| Exact Sciences Corporation | $21.36 | 2025 | Cologuard Collection Kit |
| Ascend Therapeutics US, LLC | $20.56 | 2023 | |
| Cosette Pharmaceuticals INC. | $19.81 | 2024 | Vyleesi |
| Organon LLC | $16.74 | 2024 | |
| Myovant Sciences INC. | $16.35 | 2021 | |
| Minerva Surgical, INC | $15.52 | 2019 | |
| Mission Pharmacal Company | $14.84 | 2019 | |
| Avion Pharmaceuticals | $12.06 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lily Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.